Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: Results from a randomized study

Pediatric Infectious Disease Journal

Volumn 30, Issue 3, 2011, Pages

  Esposito, Susanna ^a   Birlutiu, Victoria ^b   Jarcuska, Pavol ^c   Perino, Antonio ^d   Man, Sorin Claudiu ^e   Vladareanu, Radu ^f   Meric, Dorothée ^g   Dobbelaere, Kurt ^g   Thomas, Florence ^g   Descamps, Dominique ^g  

^a UNIVERSITY OF MILAN   (Italy)

^b Emergency Clinic Hospital   (Romania)

^c P J AFÁRIK UNIVERSITY   (Slovakia)

^d UNIVERSITY OF PALERMO   (Italy)

^e IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^f CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^g GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

adolescent; alternative dosing schedule; human papillomavirus; human papillomavirus vaccines; immunology

Indexed keywords

ANTIBODY; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; STANDARD;

EID: 79951679940     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318206c26e     Document Type: Article

References (25)

1. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006;20:207-225. (Pubitemid 43380597)
2. Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-265. (Pubitemid 34293391)
3. Muñoz N, Bosch FX, Castellsagué X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278-285. (Pubitemid 38924707)
4. Muñoz N, Bosch FX, de Sanjoseα S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527. (Pubitemid 36159887)
5. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a metaanalysis update. Int J Cancer. 2007;121:621-632. (Pubitemid 46986496)
6. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564-571. (Pubitemid 46771257)
7. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161-2170. (Pubitemid 46977438)
8. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301-314.
9. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-1765. (Pubitemid 39488060)
10. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-1255.
11. The GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009;374:1975-1985.
12. Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin. 2009;5:332-340.
13. Cherry DK, Hing E, Woodwell DA, et al. National Ambulatory Medical Care Survey: 2006 summary. Natl Health Stat Report. 2008;3:1-39.
14. Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:997-1001.
15. Silins I, Kallings I, Dillner J. Correlates of the spread of human papillomavirus infection. Cancer Epidemiol Biomarkers Prev. 2000;9:953-959.
16. Dessy FJ, Giannini SL, Bougelet CA, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin. 2008;4:425-434.
17. Wheeler CM, Bautista OM, Tomassini JE, et al. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine. 2008;26:686-696.
18. Koulova A, Tsui J, Irwin K, et al. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine. 2008;26:6529-6541.
19. Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries - key challenges and issues. N Engl J Med. 2007;356:1908-1910. (Pubitemid 46740300)
20. Wright TC Jr, Huh WK, Monk BJ, et al. Age considerations when vaccinating against HPV. Gynecol Oncol. 2008;109(suppl 2):S40-S47. (Pubitemid 351649370)
21. Dempsey AF, Davis MM. Overcoming barriers to adherence to HPV vaccination recommendations. Am J Manag Care. 2006;12(suppl 17):S484-S491. (Pubitemid 46053399)
22. Tissot AM, Zimet GD, Rosenthal SL, et al. Effective strategies for HPV vaccine delivery: the views of pediatricians. J Adolesc Health. 2007;41:119-125. (Pubitemid 47058987)
23. Herzog TJ, Huh WK, Downs LS, et al. Initial lessons learned in HPV vaccination. Gynecol Oncol. 2008;109(suppl 2):S4-S11. (Pubitemid 351637606)
24. Cervarix [product information]. GlaxoSmithKline Australia Pty Ltd. April 1, 2010. Available at: http://www.gsk.com.au. Accessed October 18, 2010.
25. Romanowski B, Schwarz T, Ferguson L, et al. HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the standard 3-dose schedule. In: EUROGIN; February 17-20, 2010; Monte Carlo, Monaco. Abstract SS 11-5. Available at: http://www.eurogin.com/2010/EUROGIN2010-Abstracts.pdf. Accessed October 18, 2010.